PEAR1 GG genotype is a risk factor for AA and ADP platelet aggregation, and the GA+AA genotype is associated with hyperglycemia, which affects one-year outcomes.
Cohort (n=171)
No
Does PEAR1 genetic polymorphism impact clinical outcomes and platelet aggregation in Chinese patients receiving dual antiplatelet therapy after percutaneous coronary intervention?
PEAR1 genetic polymorphisms are associated with platelet aggregation and hyperglycemia, which may influence one-year clinical outcomes in Chinese patients on DAPT post-PCI.
Background: Patients might still experience major adverse cardiovascular events even with dual antiplatelet therapy after percutaneous coronary intervention. Our study aimed to explore the impact of gene polymorphism on clinical outcomes in one-year follow-up. Methods: A total of 171 patients treated with dual antiplatelet therapy after percutaneous coronary intervention from April to December 2020 in the first hospital of Jilin University enrolled in this study. Results: PEAR1 genetic polymorphisms was associated with the arachidonic acid (AA) and adenosine diphosphate (ADP) platelet aggregation. Hyperglycemia was associated with the rate of major adverse cardiovascular events. PEAR1 GA+AA genetic genetic polymorphisms is associated with hyperglycemia. Conclusion: PEAR1 GG is a risk factor for AA and ADP platelet aggregation. Hyperglycemia can effect the one-year outcome. PEAR1 GA+AA genetic polymorphisms are associated with hyperglycemia.
Hu et al. (Fri,) conducted a cohort in Percutaneous coronary intervention (n=171). PEAR1 polymorphism was evaluated on Platelet aggregation and major adverse cardiovascular events. PEAR1 GG genotype is a risk factor for AA and ADP platelet aggregation, and the GA+AA genotype is associated with hyperglycemia, which affects one-year outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: